Aeron Biotechnology, Inc. proposes to develop a simple, economical, and rapid in vitro breast cancer cell bioassay that can be used to detect, distinguish between, and determine the bioactivity of estrogens and antiestrogens. To distinguish between estrogens and antiestrogens we will monitor differences in their molecular actions on estrogen receptor (ER) binding and activation, ER processing, end product induction, and cell proliferation in intact breast cancer cell lines. The proposed in vitro bioassay will have several commercial applications. It will provide a simple means by which a large panel of drugs, plant extracts, foodstuffs, etc. can be screened rapidly for estrogenic or antiestrogenic (ie, anticancer) activity. At the clinical level the bioassay will be useful for monitoring serum antiestrogen content and overall bioactivity in breast cancer patients receiving antiestrogen therapy.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HD027738-01
Application #
3499857
Study Section
Reproductive Endocrinology Study Section (REN)
Project Start
1991-05-01
Project End
1991-10-31
Budget Start
1991-05-01
Budget End
1991-10-31
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Aeron Biotechnology, Inc.
Department
Type
DUNS #
City
San Leandro
State
CA
Country
United States
Zip Code
94577